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Open access under the Elsevis u m m a r y
To examine the impact of late treatment-related xerostomia and dysphagia on health-related quality of
life (HRQOL) in head and neck cancer (HNC) patients after radiotherapy. A multi-center cross-sectional
survey was performed. Patients with a follow-up of at least 6 months after curative radiotherapy, without
evidence of recurrent disease were eligible for inclusion. The Euroqol-5D questionnaire (EQ-5D) was
ﬁlled out and toxicity was scored and converted to the RTOG scale. The EQ-5D measures generic HRQOL
in terms of utility and visual analogue scale (VAS) scores. Missing data on the EQ-5D were imputed using
multiple imputation. HRQOL was compared between subgroups of patients with and without toxicity.
Subsequently, the impact of xerostomia and dysphagia on HRQOL was analyzed using multivariate
regression analyses. Both analyses were performed separately for utility scores and VAS scores. The study
population was composed of 396 HNC patients. The average utility and VAS scores were 0.85 (scale 0–1)
and 75 (scale 0–100). Subgroups of patients with xerostomia and/or dysphagia showed statistically sig-
niﬁcantly lower utility and VAS scores (P = 0.000–0.022). The multivariate regression model showed that
xerostomia and dysphagia were negative predictors of both utility and VAS scores. Other factors which
inﬂuenced HRQOL in at least one of the two regression models were: sex, tumor location and the addition
of surgery to radiotherapy. Xerostomia and dysphagia diminish generic HRQOL. Moreover dysphagia
affects patients’ HRQOL stronger than xerostomia.
 2011 Elsevier Ltd. Open access under the Elsevier OA license.Introduction
An increasing number of options become available for the treat-
ment of head and neck cancer (HNC). Traditionally, treatment deci-
sions were primarily based on local tumor control and the length of
survival. However, treating HNC often involves a trade-off betweenation Oncology (MAASTRO),
iology, Maastricht University
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er OA license.(disease-free) survival and treatment-related toxicity. After radio-
therapy, in particular xerostomia and dysphagia negatively affect
health-related quality of life (HRQOL).1,2 Therefore, the length of
survival after treatment has to be weighed against the quality of
survival. As a result, HRQOL and factors inﬂuencing HRQOL (such
as treatment-related toxicity) are increasingly recognized as
important treatment outcomes in HNC.1,3–5
To take into account HRQOL, disease-speciﬁc measures are of-
ten used. Although these questionnaires are relevant for patients
and physicians, the main disadvantage of disease-speciﬁc mea-
sures is their inability to compare HRQOL in different disease areas.
In contrast, generic HRQOL can be compared in different disease
areas. Measures of generic HRQOL assess the preferences of indi-
viduals for a certain health status; the more preferable the out-
come, the higher the score.6 This can be measured by inquiring
how patients value their own health status (patients’ perspective)
or based on the preferences of the society (general public perspec-
tive). Preferences for health states can be combined with life
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main advantage of QALYs is that they capture life expectancy and
quality of life in a single measure.6 This is useful to inform the
aforementioned trade-off between length of survival and treat-
ment-related toxicity (quality of survival).
Previous studies have assessed health state preferences in
HNC.7–11 However, to our knowledge, no study provided health
state preferences based on subgroups distinguished by treat-
ment-related toxicity for primary treated HNC patients. Hence,
knowledge on the impact of toxicity on generic HRQOL is lacking.
Therefore, we aimed to examine the impact of late treatment-re-
lated xerostomia and dysphagia on HRQOL (patient and general
public perspective) in disease free HNC patients treated with
radiotherapy.
The aim of this study was twofold: (1) to compare HRQOL
across subgroups subdivided by xerostomia and dysphagia and
(2) to examine the inﬂuence of late treatment-related toxicity on
HRQOL.Materials and methods
Conceptual model
To examine the inﬂuence of late treatment-related toxicity on
HRQOL, we constructed a conceptual model (Fig. 1). In order to
minimize multicollinearity in our analyses, we only included fac-
tors that are directly related to HRQOL, excluding indirect factors
(i.e. variables that inﬂuence HRQOL through other variables).
HRQOL is negatively affected by radiotherapy induced xerosto-
mia and dysphagia.1,2,12 Since dysphagia may be the consequence
of xerostomia, these outcome measures might correlate or even
interact. Next to these main variables of interest, other potentiallyFigure 1 Conceptual model.predictive factors were subdivided into patient related factors, dis-
ease related factors and treatment-related factors. Patient related
factors include sex and age; HRQOL scores are likely to decrease
with increasing age and tend to be lower for females.13–15 Disease
related factors include tumor location and disease stage. Tumor
location has a varying impact on HRQOL.1,2,16,17 In contrast, disease
stage is unlikely to directly affect HRQOL.1,2,16,17 In case of a lower
HRQOL for patients with advanced disease stage, the decreased
HRQOL is suggested to be related to cancer treatment, treatment
toxicity and/or disease progression rather than to cancer stage di-
rectly2,16,18 Hence, disease stage can be considered as an indirect
predictor of HRQOL and is for this reason not included in our con-
ceptual model. Finally, with regard to treatment-related factors,
the combination of radiotherapy with surgery or chemotherapy
is suggested to have a negative inﬂuence on HRQOL.1,16 The inter-
val after radiotherapy (follow-up period) has a varying impact on
HRQOL.1,19
Data collection
From June 2009 to March 2010, a multi-center cross-sectional
surveywas performed during planned follow-up visits in twoDutch
hospitals.20 The study population consisted of HNC patients, who
were treated with curative intend by radiotherapy alone or com-
bined with surgery and/or chemotherapy. Patients with a follow-
up period of 6 months or longer after the start of radiotherapy and
without evidence of recurrent disease were eligible for inclusion.
The EuroQol-5D questionnaire21 (EQ-5D) was ﬁlled out in the
hospital before the patients visited their physician. During the fol-
low-up visit, severity of xerostomia and dysphagia was scored by a
trained researcher (radiation technologist) or the treating physi-
cian and converted to the RTOG scale22 (Appendix 1). The following
data were retrieved from patients’ medical records: date and type
of initial treatment, primary tumor location and initial tumor
stage. This study was approved by the Institutional Review Board.
EuroQol-5D
The EQ-5D is the most frequently used multi-attribute health
status classiﬁcation system and is recommended by the National
Institute for Health and Clinical Excellence.6,21,23–25 The EQ-5D
consists of questions considering ﬁve dimensions of generic
HRQOL (mobility, self-care, usual activities, pain/discomfort and
anxiety/depression).21 The answers to these questions can be com-
bined to calculate health state preferences (so-called utility scores)
from a general public perspective using a scoring function. This
scoring function was based on the preferences of 2.997 UK respon-
dents, who valued 42 different health states from the EQ-5D using
the time trade-off method (TTO).26 Utility scores calculated by this
scoring function range from 0.59 (health state worse than death,
severe problems in all ﬁve dimensions), through 0 (death) to 1 (full
health, no problems in all dimensions). Next to the ﬁve questions, a
visual analogue scale (VAS) is included in the EQ-5D that ranges
from 0 (worst imaginable health state) to 100 (best imaginable
health state).21 The VAS measures the patients’ self-rated HRQOL
(patients’ perspective).27
Data analyses
Missing data
Patients with missing data for late toxicity scores were ex-
cluded from the analyses. As recommended for handling missing
HRQOL data,28 missing data on the EQ-5D were replaced using
multiple imputation. To impute the missing values on the ﬁve
questions and the VAS score of the EQ-5D, ﬁve datasets were
created (m = 5). The imputation model included the variables
Table 1
Characteristics of the study population.a
Patient characteristics
Sex
Male 276 70%
Female 120 30%
Age (years)
Mean (Sd) 63.2 (11.8)
Minimum, maximum 20 99
Follow-up period (months)
Median (IR) 20 (23.0)
Minimum, maximum 6 152
Disease characteristics
Tumor location
Oral cavity and lip 51 13%
Pharynx 115 29%
Larynx 125 32%
Nasal cavity and sinuses 20 5%
Salivary gland 23 6%
Otherb 49 12%
Unknown 13 3%
Tumor classiﬁcation
Tis 8 2%
T0 17 4%
T1 92 23%
T2 115 29%
T3 55 14%
T4 82 21%
Unknown 27 7%
Node classiﬁcation
N0 194 49%
N1 57 14%
N2 121 31%
N3 9 2%
Unknown 15 4%
Stage (UICC)
0 7 2%
I 55 14%
II 59 15%
III 78 20%
IV 139 35%
Unknown 58 15%
Treatment characteristics
Surgery of the primary tumor
No 258 65%
Yes 138 35%
Chemotherapy
No 339 86%
Yes 57 14%
Abbreviation: Sd, standard deviation; RT, radiotherapy; IR, interquartile range.
a Values are numbers/percentages unless stated otherwise.
b Including skin and unknown primary tumors.
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VAS of the EQ-5D. Categorical variables were imputed as scale vari-
ables and variables containing more than two categories were con-
verted into dummy variables.29,30 After multiple imputation,
values for the separate questions of the EQ-5D were converted
back to categorical variables.29
To obtain pooled estimates of themean, variance and parametric
tests the method as described by Rubin31 and more recently by
Carlin et al.32 was used. There is no generally accepted method for
pooling the (adjusted) R2, medians, quartiles and non-parametric
tests. The (adjusted) R2 was pooled by averaging the separate values
for the (adjusted) R2 from all ﬁve regression analyses. Medians and
quartiles were pooled by obtaining the median and quartiles of all
ﬁve imputed datasets combined. Non-parametric tests were pooled
by averaging the test statistic for the separate tests for all ﬁve
imputed datasets, which was subsequently used to calculate
p-values.
Analyses
First, descriptive statistics were computed for the population
characteristics.
Second, we examined differences in utility and VAS scores be-
tween subgroups with toxicity and without toxicity. For this pur-
pose, patients were subdivided according to grade 0, 1, 2 and P3
for both xerostomia and dysphagia. Only subgroups withP10 pa-
tients were included in the analyses. Subsequently, skewness and
kurtosis of the HRQOL distribution within these subgroups were
examined. If the skewness and kurtosis fell between 2.0 and
2.0, the differences between subgroups were compared using one
way analysis of variance (ANOVA) and if signiﬁcant multiple paired
Student’s t-tests were performed. Kruskal–Wallis tests and if sta-
tistically signiﬁcant pairwise comparison Mann–Whitney U tests
were performed if the skewness or kurtosis exceeded this range.
Third, to test the conceptualmodel presented in Fig. 1, utility and
VAS scoreswere separately included as dependent variables inmul-
tivariate regression analyses. The variables which were considered
to inﬂuence HRQOL were included in the regression model as inde-
pendent variables. Grade of xerostomia and dysphagia, as well as
sex, tumor location, surgery of the primary tumor and chemother-
apywere included as categorical variables. Xerostomia and dyspha-
gia were subdivided into dummy variables for grade 0 (reference
category), 1, 2 and P3. For tumor location dummy variables were
created for oral cavity and lip, pharynx, larynx and other sites (refer-
ence category). Larynx and pharynx were separate categories since
laryngeal carcinomas are typically early stage tumors and subse-
quently treated with limited radiation ﬁelds as opposed to pharynx
carcinomas which are mostly locally advanced and treated with
large radiation ﬁelds. Further, age and follow-up period after radio-
therapy were included as scale variables. Since there is a possible
interaction between xerostomia and dysphagia, effect modiﬁcation
(by means of an interaction term) was considered between these
two variables.
Independently of the signiﬁcance, none of the potentially inﬂu-
encing variables were excluded from the regression model. Only
the interaction term between xerostomia and dysphagia was ex-
cluded if not statistically signiﬁcant. The ﬁnal regression models
were checked for assumptions of linear regression.
All analyses were performed using SPSS 17.0. P-values <0.05
were considered statistically signiﬁcant.
Results
Population characteristics
Altogether, 92% of all approached patients agreed to participate.
In total 426 patients ﬁlled out the questionnaire, 30 of thesepatients were excluded since toxicity data were missing. This re-
sulted in a study population of 396 patients of which 55 patients
(14%) had missing values on the EQ-5D which were imputed. Pop-
ulation characteristics are presented in Table 1. The average utility
and VAS scores among all 396 patients were 0.85 (sd: 0.18) and 75
(sd: 15), respectively.
HRQOL among patients subdivided by xerostomia and dysphagia
Subgroups were categorized by grades of xerostomia and/or
dysphagia (based on the RTOG scale). In total, 84 patients (21%)
had no xerostomia or dysphagia. Xerostomia was more prevalent
than dysphagia (Table 2).
For the utility scores, a ceiling effect (the scores are clustered
around the upper end of the scale) was observed for the subgroup
without toxicity. This resulted in a distribution with a high skew-
ness (2.4) and kurtosis (7.2). For VAS scores, the skewness and
kurtosis were within the proposed range. Therefore, subgroup
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scores and using parametric tests for VAS scores.
Utility scores were signiﬁcantly different between subgroups
(Kruskal–Wallis test, P < 0.001). Pairwise comparisons showed sig-
niﬁcantly higher utility scores for patients without toxicity com-
pared to patients with Pgrade 1 dysphagia independently of the
grade of xerostomia. For patients with dysphagia grade 0, average
utility scores ranged between 0.91 (xerostomia grade 0) and 0.85
(xerostomia grade 2). For dysphagia grade 1 this ranged between
0.84 and 0.82 and between 0.80 and 0.76 for Pgrade 2 dysphagia
(Table 2 and Fig. 2).
Also VAS scores were signiﬁcantly different among subgroups
(ANOVA, P < 0.001). Pairwise comparisons showed signiﬁcantly
lower VAS scores if patients had Pgrade 1 for both xerostomia
and dysphagia, except for the subgroup with grade 1 xerostomia
and grade 2 dysphagia. For patients with dysphagia grade 0, aver-
age VAS scores ranged between 80 (xerostomia grade 0) and 76
(xerostomia grade 2). For dysphagia grade 1 this ranged between
74 and 70 and between 74 and 65 forPgrade 2 dysphagia (Table 2
and Fig. 2).
Factors inﬂuencing HRQOL
Utility scores were signiﬁcantly negatively affected by grade 2
andP3xerostomia in themultivariate regressionanalyses (Table3).
This was also true for dysphagia grade 1 and grade 2. Grade 1 xero-
stomia andPgrade 3 dysphagia had no signiﬁcant impact on utility0
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Table 3
Multivariate regression model.a
Final model (dependent variable = utility score)
R2 = 42%,b Adjusted R2 = 17%c
Independent variables Beta Se P-value
Constant 0.836 0.057 0.000
Treatment toxicity
Xerostomiad
Grade 1 0.013 0.021 0.540
Grade 2 0.059 0.028 0.040
Grade 3+ 0.336 0.123 0.006
Dysphagiad
Grade 1 0.059 0.021 0.005
Grade 2 0.126 0.029 0.000
Grade 3+ 0.074 0.040 0.060
Patient characteristics
Sex
Male 0.052 0.019 0.006
Age 0.000 0.001 0.747
Disease characteristics
Tumor locationd
Oral cavity and lip 0.081 0.030 0.006
Pharynx 0.063 0.027 0.018
Larynx 0.032 0.026 0.226
Treatment characteristics
Surgery of the primary tumor
Yes 0.062 0.022 0.006
Chemotherapy
Yes 0.040 0.027 0.148
Follow-up period 0.000 0.000 0.499
Interaction
Xerostomia and Dysphagia – – ns
R2 = 39%b, Adjusted R2 = 16%c
Constant 79.4 4.9 0.000
Treatment toxicity
Xerostomiad
Grade 1 1.6 1.9 0.412
Grade 2 7.7 2.6 0.003
Grade 3+ 8.2 11.1 0.460
Dysphagiad
Grade 1 5.6 1.8 0.002
Grade 2 7.2 3.0 0.026
Grade 3+ 10.8 3.4 0.002
Patient characteristics
Sex
Male 1.4 1.7 0.397
Age 0.1 0.1 0.310
Disease characteristics
Tumor locationd
Oral cavity and lip 5.9 2.7 0.031
Pharynx 4.7 2.3 0.040
Larynx 1.9 2.2 0.398
Treatment characteristics
Surgery of the primary tumor
Yes 4.0 2.0 0.043
Chemotherapy
Yes 4.4 2.4 0.068
Follow-up period 0.0 0.0 0.757
Interaction
Xerostomia and Dysphagia – – ns
Abbreviations: Se, standard error; ns, not statistically signiﬁcant.
a For the complete case analyses see Appendix.
b R2 = the fraction of the total squared error that is explained by the regression
model.38
c Adjusted R2 = measure indicating how much variance in the outcome would be
accounted for if the model had been derived from the population from which the
sample was taken.38
d Reference category for dummy variables was Grade 0 toxicity and other tumor
locations.
772 B.L.T. Ramaekers et al. / Oral Oncology 47 (2011) 768–774scores. Other signiﬁcant inﬂuencing variables were sex, tumor loca-
tion and whether surgery of the primary tumor was performed. Theinteraction term for xerostomia and dysphagia was not signiﬁcant
and therefore excluded from the regression model.
VAS scores were signiﬁcantly negatively inﬂuenced by grade 2
xerostomia in the multivariate regression analyses (Table 3). Also,
all grades of dysphagia (grade 1, 2 andP3) had a signiﬁcantly neg-
ative impact on VAS scores. Xerostomia grade 1 andP3 had no sig-
niﬁcant impact on VAS scores. Other statistically signiﬁcant
variables in the regression model were: tumor location, whether
surgery of the primary tumor was performed and whether patients
received chemotherapy. The interaction term for xerostomia and
dysphagia was not statistically signiﬁcant and therefore excluded
from the regression model.
The regression models were checked for the assumptions of lin-
ear regression and no severe deﬁciencies were observed.Discussion
To the best of our knowledge, this study was the ﬁrst to analyze
the impact of late treatment-related toxicity on patient-rated util-
ity and VAS scores in HNC. Our analyses demonstrated that dys-
phagia and xerostomia both have a negative impact on HRQOL.
Moreover, dysphagia had the largest impact on HRQOL. Except
for age, follow-up period and whether patients received chemo-
therapy all independent variables reported in the conceptual mod-
el (Fig. 1) were signiﬁcant predictors of HRQOL in at least one of
the two regression analyses. The relations were as expected, except
for surgery. The complete case analyses resulted in comparable
regression models (Appendix 2).
Potential limitations of this study included the low number of
patients with grade P3 toxicity (Table 2). This might explain the
fact that grade P3 dysphagia was not a signiﬁcant predictor of
utility scores. The same may apply to grade P3 xerostomia for
VAS scores. Also, the cross-sectional design and hence the inability
to correct for baseline HRQOL may be considered as a limitation.
However, we corrected for potentially confounding variables and
to our knowledge there was no rationale to assume that the HRQOL
before treatment was on average different between the subgroups
subdivided by treatment toxicity. Therefore, the impact of late
treatment-related toxicity on HRQOL in our study can probably
not be attributed to the cross-sectional design. Nevertheless, pro-
spective studies measuring utility and VAS scores in HNC patients
with different grades of toxicity are needed to conﬁrm our results.
Finally, we included patients who had a follow-up period of at least
6 months from treatment start. This includes patients who have
been studied 4–5 months following completion of radiotherapy.
It is unclear whether xerostomia and dysphagia have stabilized
after this period. However, additional analyses showed that if the
21 patients (5%) with a shorter follow-up than 6 months from
treatment completion were excluded, the HRQOL estimates strati-
ﬁed by xerostomia and dysphagia remained similar.
The current study showed on average relatively higher utility
than VAS scores. In contrast with our results, previous studies indi-
cated that patients with a speciﬁc condition (patients’ perspective)
are inclined to place higher scores for their own health state com-
pared with non-patients (general public perspective), presumably
due to adaptation.33–36 However, corresponding with our results,
most studies indicated that due to differences in measurement
methods, utility scores based on the TTO method (as in this study)
are higher than VAS scores.6,33 Despite these abovementioned dif-
ferences between utility and VAS scores, the decrements between
the subgroups subdivided by xerostomia and dysphagia were com-
parable between the two methods. Therefore, the differences be-
tween utility and VAS scores probably represent an overall shift
in HRQOL for all subgroups and do not alter the estimated impact
of xerostomia and dysphagia on HRQOL.
B.L.T. Ramaekers et al. / Oral Oncology 47 (2011) 768–774 773Previously, utility scores in HNC have been estimated using var-
ious methods.7–11 Based on the EQ-5D ﬁlled out by 50 oncology
nurses, Brown et al. reported an average utility score of 0.86 for
post-treatment HNC patients with loco-regional disease control.7
This corresponds with the overall average utility score of 0.85 in
our study. Ringash et al. applied the TTO method in 112 disease
free laryngeal cancer patients resulting in a higher utility score of
0.91.10 Due to difference in patient populations or subgroups it
was not possible to compare utility scores from the other studies
with our results.8,9,11
Marra et al.,37 deﬁned0.03 as aminimally importantdifference in
utility scores (measured by the EQ-5D). Accordingly, the main clin-
ical implications of our results are that treatment strategies aimedat
reducingdysphagia and/or xerostomiahave thepotential to result in
ameaningful improvement of generic HRQOL. This emphasizes that
next to the expected length of survival also treatment toxicity
should be consideredwhen treatment choices aremade. Our results
can be used to inform this trade-off. In consideration of this trade-
off, xerostomia is more prevalent than dysphagia, whereas dyspha-
gia has a higher impact on HRQOL than xerostomia. Therefore, pre-
venting xerostomia could beneﬁt more patients, whereas
preventing dysphagia might have a larger beneﬁt per patient.
To reduce treatment toxicity, it may be useful to focus on pa-
tients who have the highest risk of experiencing xerostomia and/
or dysphagia. In our study population, 84 patients (21%) had no
toxicity. Compared with the 312 patients (79%) with any grade of
toxicity, the patient group without toxicity consisted of less pa-
tients with advanced disease stage (III/IV: 27% versus 62%), had rel-
atively less pharyngeal cancer patients (29% versus 43%) and more
laryngeal cancer patients (36% versus 5%). Hence, patients with ad-
vanced disease stage and/or pharyngeal cancer may have a higher
chance of experiencing xerostomia and/or dysphagia. However,
this needs to be conﬁrmed in prospective studies.
In conclusion, our results can be used to support clinical deci-
sion making. They underscore the importance that, next to survival
data, clinical studies examine toxicity and its impact on generic
HRQOL. This assists the trade-off between length and quality of
survival. Our study suggests that xerostomia and dysphagia have
a negative impact on HRQOL; moreover it was found that dyspha-
gia affects patients’ HRQOL stronger than xerostomia.
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